Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTcP-Hib-MCV4 vaccine in children (2 months to 6 years)
NCT07203755Phase 1Recruiting
- Sponsor
- CanSino Biologics Inc.
- Start
- Dec 2025
- Primary completion
- Feb 2029
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of diphtheria, tetanus, and acellular pertussis vaccine + haemophilus influenzae type b vaccine + quadrivalent meningococcal conjugate vaccine in diphtheria, Tetanus, pertussis and 2 more, sponsored by CanSino Biologics Inc. Primary endpoint: Incidence of adverse reactions at 14 days. Started Dec 2025; status: recruiting.
02
Drugs
diphtheria, tetanus, and acellular pertussis vaccine + haemophilus influenzae type b vaccine + quadrivalent meningococcal conjugate vaccine
03
Conditions
diphtheriaTetanuspertussismeningococcal meningitisHaemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT07203755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07203755.